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Data is presented that was utilized as the basis for Bayesian network
modeling of inﬂuence pathways focusing on the central role of a
polymorphism of plasminogen activator inhibitor-2 (PAI-2) on
recurrent cardiovascular disease risk in patients with high levels of
HDL cholesterol and C-reactive protein (CRP) as a marker of inﬂam-
mation, “Inﬂuences on Plasminogen Activator Inhibitor-2 Poly-
morphism-Associated Recurrent Cardiovascular Disease Risk in
Patients with High HDL Cholesterol and Inﬂammation” (Corsetti et al.,
2016; [1]). The data consist of occurrence of recurrent coronary
events in 166 post myocardial infarction patients along with 1. clinical
data on gender, race, age, and body mass index; 2. blood level data on
17 biomarkers; and 3. genotype data on 53 presumptive CVD-related
single nucleotide polymorphisms. Additionally, a ﬂow diagram of thevier Inc. This is an open access article under the CC BY license
/j.atherosclerosis.2016.04.017
nd Laboratory Medicine University of Rochester Medical Center 601 Elm-
85 275 4907; fax: þ1 585 273 3003.
.edu (J.P. Corsetti).
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J.P. Corsetti et al. / Data in Brief 8 (2016) 98–104 99Bayesian modeling procedure is presented along with Bayesian net-
work subgraphs (root nodes to outcome events) utilized as the data
from which PAI-2 associated inﬂuence pathways were derived (Cor-
setti et al., 2016; [1]).
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Clinical research
ore speciﬁc subject
areaCardiovascular disease riskype of data Text ﬁle and ﬁgures
ow data was
acquiredProspective studyata format Raw, analyzed
xperimental factors Determination of clinical, blood biomarker, and genetic polymorphism
parameters
xperimental features Recurrent coronary events followed in 166 post-MI patients for 26
months
ata source location USA
ata accessibility Data are within this articleDValue of the data Data on recurrent coronary events in post-MI patients having concurrently high levels of HDL-C
and CRP are well-suited for studies challenging the notion of HDL as the “good cholesterol”.
 The data may be instrumental in further elucidation of the role of inﬂammation in the dysfunc-
tional transformation of HDL from anti-atherogenic to pro-atherogenic.
 The multivariable data involving clinical, blood biomarker, and genetic polymorphism variables
provide opportunities for the application of advanced knowledge discovery techniques in a holistic
manner potentially leading to new insights on the pathophysiology of cardiovascular disease.
 The three Bayesian network subgraphs (root nodes to outcome events) represent data that for the
variables in a subgraph present all intervening inﬂuence relationships some of which may be
worthy of further explorations in future studies.1. Data
The data (data ﬁle 1) consist of values of 4 clinical parameters (gender, age, race, BMI) along with
17 blood biomarkers and 53 SNPs all presumptively associated with cardiovascular disease risk in 166
non-diabetic post-MI patients having concurrently high levels of HDL-C and CRP. The data also
include cardiovascular disease outcomes (cardiac death, MI, unstable angina) in the patients with a
mean follow-up time of 26 months. Additional data (Figs. 1–3) include 3 Bayesian network subgraphs
(root nodes to the node representing recurrent coronary event outcome that in each case was pre-
speciﬁed as a terminal node) which delineate three parent sets of outcome that in each case include a
PAI-2 SNP (rs6095) as one of the two parents of outcome.
Fig. 1. Bayesian network subgraph (root nodes to outcome events node pre-speciﬁed as a terminal node) demonstrating the
PAI-2 SNP (rs6095) and the p22phox SNP (rs4673) as parents of outcome events as well as demonstrating further inﬂuence
relationships among all contributing variables.
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2.1. Experimental design
High levels of HDL-C were chosen to avoid potentially confounding effects on CVD risk by low
levels of HDL-C. From the study using Bayesian network modeling, further data were derived con-
sisting of three subgraphs (root nodes to recurrent coronary outcome events). These subgraphs
delineated inﬂuence relationships among contributing variables with each of the three having in-
common a PAI-2 SNP (rs6095) as a parent of outcome. A ﬂow diagram of the generation of the data is
given in Fig. 4.
2.2. Study population
The study population consisted of non-diabetic post-MI patients having concurrently high levels of
HDL-C and CRP [2] that were drawn from the Thrombogenic Factors and Recurrent Coronary Events
(THROMBO) postinfarction study [3] using outcome event mapping, a graphical approach for the
identiﬁcation of speciﬁc patient subgroups [4]. The THROMBO study was an investigation of blood
Fig. 2. Bayesian network subgraph (root nodes to outcome events node pre-speciﬁed as a terminal node) demonstrating the
PAI-2 SNP (rs6095) and the ﬁbrinogen SNP (rs4220) as parents of outcome events as well as demonstrating inﬂuence rela-
tionships among all contributing variables.
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mined two months after having an MI with subsequent following for an average of 26 months for
recurrent coronary events (cardiac death, additional MI, unstable angina). The THROMBO study was
carried out with approval of and according to guidelines of Research Subjects Review Boards of
participating institutions including acquisition of written informed consent.
2.3. Laboratory analyses
Fasting sera and plasma were prepared two months after index MI. Apolipoprotein B (apoB), total
cholesterol, lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, apolipoprotein A-I (apoA-I),
HDL, triglyceride, glucose, insulin, lipoprotein(a) (Lp(a)), plasminogen activator inhibitor-1 (PAI-1),
von Willibrand factor antigen (vWF), ﬁbrinogen, D-dimer, factor VII, and factor VIIa were determined
as described previously [3]. CRP and serum amyloid A (SAA) were determined by immunonephelo-
metry [5]. Genotypings of 53 SNPs presumptively associated with cardiovascular disease risk were
Fig. 3. Bayesian network subgraph (root nodes to outcome events node pre-speciﬁed as a terminal node) demonstrating the
PAI-2 SNP (rs6095) and the LRP1 (low-density lipoprotein receptor-related protein-1) SNP (rs1800156) as parents of outcome
events as well as demonstrating inﬂuence relationships among all contributing variables.
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standard techniques as described previously [6,7].
2.4. Bayesian network modeling
Bayesian network (BN) modeling generates a directly interpretable graphical representation of the
joint probability distribution over a set of random variables, in this case, over our data comprised of
four clinical, 17 blood biomarker, and 53 SNP variables along with recurrent coronary events pre-
speciﬁed as a terminal node. What this means is that a network is a pictorial representation of the
inﬂuences that variables have on each other. In the case at hand, it allows identiﬁcation of pathways
of inﬂuence that the variables have on each other in leading to recurrent coronary events. In the
representation, variables appear within enclosures denoted as “nodes” and inﬂuences between
variables appear as arrows pointing from a “parent” node to a “child” node. A key property of BNs for
the current work is that for a terminal node (a node without any children), the direct and presumably
sole causal inﬂuences on that terminal node are its parent nodes. In the present case, as stated above,
recurrent coronary events were pre-speciﬁed as a terminal node and thus, identiﬁcation of its parent
node variables would result in identiﬁcation of signiﬁcant and direct inﬂuences on recurrent risk. In
addition, identiﬁcation of node variables and relationships in the locale of the recurrent risk node
potentially could provide information more generally related to pathophysiologic mechanisms
leading to risk.
Thus, a series of BNs based on the data of the current study were generated and ranked using an
estimation algorithm and model selection criteria, respectively, as described in detail previously [1].
Using this approach, the 500 best-scoring BNs were retained for further consideration. The BNs were
then partitioned based upon commonality of the parental nodes of outcome. Remarkably, only ﬁve
partition patterns of the parental node of outcome resulted three of which demonstrated in-common
Fig. 4. Flow diagram of Bayesian network modeling approach.
J.P. Corsetti et al. / Data in Brief 8 (2016) 98–104 103a SNP of PAI-2 (rs6095) accounting for 440 of the 500 BNs, thus highlighting the key role of PAI-2 in
recurrent risk. To focus on the regions of the three BNs most closely related to outcome and in view of
the complexity of the full BNs, corresponding subgraph data (root nodes to outcome) were generated.Acknowledgments
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